OrganiGram Holdings Inc.
Why OrganiGram (OGI) Stock Is So Expensive Right Now
Organigram's Stock Forecast: Should You Buy the Penny Pot Stock?
What Does President Trump Think about Marijuana?
President Trump hasn’t directly supported or opposed marijuana. In the past, he said that marijuana makes people “lose IQ points.”
Why Vaping May Not Be a Gold Mine for Cannabis Players
In recent years, vaping devices or e-cigarettes have been considered safer than tobacco cigarettes. However, the rise in vaping is now a matter of concern.
Cannabis Industry Heats Up, Trump Might Ban Vaping
Cannabis legalization is heating up. More states are coming forward to legalize marijuana. Cannabis is also gaining global popularity.
Canopy Growth Stock Rises, Oppenheimer Initiates Coverage
Oppenheimer analyst Rupesh Parikh initiated coverage on Canopy Growth stock. The analyst gave a “perform” rating with no target price.
What Do Analysts Recommend for Canopy Growth?
On December 16, Canopy Growth was trading at 26.79 Canadian dollars, implying a rise of 9.6% since its fiscal 2020 second-quarter earnings release.
Cannabis and Vaping Concerns: Will the Dream Go Up in Smoke?
Cannabis legalization is a vital topic in the US. Meanwhile, vaping related deaths continue to rise. Will vaping concerns kill the US cannabis dream?
Marijuana Vape Products Expected in Alberta Stores
AGLC will allow retail stores in Alberta to sell marijuana vape products. Consumers will likely be able to purchase cannabis vape products in the next two weeks.
Is Aphria a Good Cannabis Pick for 2020?
Aphria has successfully strengthened its position not only in Canada but also in international markets. The company reported impressive second-quarter results.
Cannabis 2.0: Aphria Gets Ready for Edibles Market
Cannabis 2.0 legalization will take place in Canada this month. Aphria plans to expand its consumer base in the vape and concentrates business.
Marijuana: Will Trump Have an Edge over Biden?
With Biden strongly opposing full-scale legalization, President Trump could turn around things. President Trump might support medical marijuana legalization.
Vaping Concerns Grow, FDA and FTC Investigate Juul
Vaping has become very popular. However, investigations by the FTC and FDA sparked more concerns. Juul’s vaping devices could cause seizures.
Valuation for Cannabis Stocks in October
The cannabis industry is fighting against the ongoing US-China trade war and recessionary worries, which have hurt valuations across the global market.
Analysts’ Outlook for Cronos Group in January
Jefferies reduced the target price for Cronos Group stock to $5.3 from $7.5. The stock’s average target price is set at 12.0 Canadian dollars.
Will Santa Claus Rally Boost Cannabis Stocks?
On December 26, a Santa Claus rally seems to be in full swing. This effect pushed the S&P 500 (SPX) and Nasdaq Composite Index (COMP) to record highs.
Cannabis 2.0 Legalization: Canada Is Ready
Federally, cannabis legalization saw daylight in Canada in 2018. The Cannabis Act legalized recreational marijuana in October 2018. Now, the country is all set for the second wave of legalization, Cannabis 2.0, which includes cannabis edibles, cannabis-infused beverages, extracts, and various other products. Let’s dig into this more. Canada’s second wave of legalization Next month, […]
Why Canopy Growth Is a ‘Buy’ before Its Earnings
Despite the surge in May, Canopy Growth is still trading at a 54.3% discount from its 52-week high of $59.74. So, should you buy the stock?
Arizona’s Marijuana Campaign Qualifies for November Ballot
Marijuana campaigns in most US states faced challenges gathering enough signatures amid the pandemic. However, Arizona got plenty of signatures.
Canopy Growth and Cronos Group’s Earnings Next Week
Canopy Growth (CGC) (WEED) and Cronos Group (CRON) are set to release their earnings next week. The cannabis sector has been on a roller coaster this year.
Raymond James Foresees a Cannabis Rebound in 2020
Cannabis stocks had a difficult 2019. Besides cannabis companies losing out on revenue and profitability, many external factors also affected the sector. While pessimism drove the industry this year, a Raymond James analyst predicts things can turn around in 2020. Let’s take a look. Raymond James feels the cannabis sector could rebound On December 16, […]
New Gallup Poll on Marijuana Legalization Support
A recent Gallup poll data found that nearly 66% of Americans support making cannabis legal. However, this figure was the same as in 2018. This suggests a standstill in the rise in support of cannabis legalization. Moreover, nine states will be voting in 2020 on measures to allow cannabis for recreational or medical use. The […]
Aurora Cannabis Releases Update on Cannabis 2.0
Aurora Cannabis (ACB) is going through a rough patch. This year, the company’s stock has lost 60.9% of its value as of December 23.
Vaping Cannabis or Smoking Tobacco: Burning Questions
During its latest earnings call, Aphria (APHA) stated that vapes and concentrates could form a major share of Canada’s recreational market by 2021.
Vaping Risks: Health Canada’s Warning, US Reports More Cases
Health Canada issued a statement warning people about vaping risks. There have been more illnesses, possibly caused by vaping, in several US states.
Why Origin House’s Acquisition Is Vital for Cresco Labs
On December 31, 2019, Origin House (OH) announced that its shareholders had approved Cresco Labs’ (CRLBF) acquisition plan.
Organigram Has Analysts Confident ahead of Q1 Earnings
Organigram is set to report its fiscal 2020 first-quarter earnings on January 14. The company’s fiscal 2019 fourth-quarter results were stable.
Marijuana Legalization Catches Federal Reserve Bank’s Attention
The spotlight is on marijuana legalization as the demand keeps surging. More states have stepped up to legalize either recreational or medical cannabis.
OrganiGram Receives Expansion License from Health Canada
On Monday, OrganiGram Holdings (NASDAQ:OGI) announced that it received a license from Health Canada to expand its Phase 5.
Cannabis Stocks in Trouble, PI Financial Cuts Target Price
Cannabis stocks see dark clouds looming. The week ending on October 11 was disastrous for the sector. Hexo stock fell after it withdrew its fiscal 2020 outlook.
Aurora Cannabis: Q3 Revenue Beat the Estimates
Aurora Cannabis saw less of an impact from COVID-19 in the third quarter. Cannabis is an essential item amid the pandemic.
Marijuana Legalization Proceeds in Montana amid COVID-19
New Approach Montana resumed its marijuana legalization campaign in May. The group submitted plenty of signatures and qualified for the November ballot.
OrganiGram Stock Falls after Disappointing Q3 Earnings
Today, OrganiGram Holdings (NASDAQ:OGI) reported its third-quarter earnings. As expected, the results were disappointing.
What to Expect from KushCo Holdings’ Q3 Earnings
KushCo Holdings will likely report its third-quarter results on Wednesday. The company will have an earnings call before the market opens.
Innovative Industrial Properties Raises More Cash amid Crisis
On June 30, Innovative Industrial Properties announced its decision to raise additional capital of $225 million through a public offering of its common stock.
Aurora Cannabis Appoints New Chief Commercial Officer
As the demand for Cannabis 2.0 products continues to rise, Aurora Cannabis announced the appointment of Miguel Martin as its new chief commercial officer.
OrganiGram Lays Off 220 Employees, Delays Q3 Earnings
To survive amid the current COVID-19 crisis, OrganiGram (NASDAQ:OGI) announced restructuring changes including a 25% cut in its workforce.
KushCo Holdings Reported Lower Q3 Results, Stock Rose 10%
KushCo Holdings’ third-quarter net revenue was $22.3 million, which was much lower than analysts’ estimate of $31.1 million.
Marijuana Legalization Hopes Rise in Nebraska for 2020
Marijuana legalization hopes never really ended in Nebraska. Signature gathering paused in the state amid the pandemic and the lockdown.
Is Aphria or OrganiGram a Better Buy for Investors?
Analysts expect Aphria to report revenues of $631.8 million in the next four quarters. Management will focus on the medical and recreational sectors.
What to Expect from OrganiGram’s Q3 Earnings
OrganiGram will likely report its third-quarter earnings before the market opens on July 21. Overall, there isn’t much hope.
Haywood Capital Markets Reduced OrganiGram’s Target Price
OrganiGram (NASDAQ:OGI) stock is trading higher before its third-quarter earnings. The stock closed with a gain of 3.9% at $1.58 on Wednesday.
Aphria Stock Rose More than 8% after Stifel’s Upgrade
Aphria (NYSE:APHA) received a bullish call from Stifel. On Monday, Stifel upgraded the stock from a “hold” to a “buy” rating.
Why Did Raymond James Downgrade OrganiGram?
On Monday, Cantech Letter reported that Raymond James downgraded OrganiGram from an “outperform” rating to a “market perform” rating.
Why Is Raymond James Bullish on Cronos Group?
Earlier this week, Rahul Sarugaser of Raymond James upgraded Cronos Group (NASDAQ:CRON) from “market perform” to “outperform.”
Canopy Growth CEO Expects US to Legalize Cannabis by 2022
Amid the growing support for cannabis legalization, Canopy Growth (NYSE:CGC) CEO David Klein expects the federal government to legalize marijuana by 2022.
Top 2 Cannabis Stocks to Buy, Interest in the Sector Reignites
After underperforming the broader equity markets in the first quarter, the cannabis sector has been showing a strong recovery in the second quarter.
Curaleaf Expands Select Brand Medical Products in Connecticut
On Monday, Curaleaf Holdings announced that it will expand its Select brand products in Connecticut. The products will be available at medical dispensaries.
Wall Street’s Expectations after Hexo’s Q3 Earnings
Hexo (TSE:HEXO) reported better-than-expected results for the third quarter of fiscal 2020 last week. The company repeatedly disappointed investors in 2019.
OrganiGram Stock Rose Due to New International Agreement
On Wednesday, OrganiGram Holdings (NASDAQ:OGI) announced that its subsidiary OrganiGram signed a supply agreement with Canndoc.
Why Does Paradigm Capital Favor OrganiGram Holdings?
Paradigm Capital analyst Corey Hammill is bullish on OrganiGram. He rated the stock as a “buy” with a target price of 4.00 Canadian dollars.
Aurora and Aphria Look Attractive for Cantor Fitzgerald
Since Aurora Cannabis reported its third-quarter earnings on May 14, its stock has more than doubled. The company is still trading 42.4% down YTD.
Why Is Raymond James Bullish on OrganiGram?
Rahul Sarugaser of Raymond James is upbeat on OrganiGram Holdings (NASDAQ:OGI). The company amended its credit facility with the Bank of Montreal.
Why OrganiGram Stock Rose More than 11% Yesterday
OrganiGram (NASDAQ:OGI) had good news for patients who use cannabis for medical purposes. The company expanded its medical cannabis offerings.
Aurora Cannabis to Enter US CBD Market, Stock Rises over 30%
On Wednesday, Aurora Cannabis (NYSE:ACB) announced that it has signed an agreement to acquire Reliva—a US-based CBD company.
Why Analysts Still Aren’t Convinced about Aurora Cannabis
Since Aurora Cannabis reported its third-quarter earnings, Piper Sandler upgraded the stock from “underweight” to “neutral.” Analysts favor a “hold” rating.
GW Pharmaceuticals Stock Rises on Higher Epidiolex Sales
On Monday, GW Pharmaceuticals reported its first-quarter earnings. The company beat analysts’ revenue, EBITDA, and EPS expectations.
Cronos Group’s Q1 Revenue Driven by Higher Marijuana Sales
Cronos Group (NASDAQ:CRON) reported its results for the first quarter of fiscal 2020 on May 8. The revenue improved from the fourth quarter of fiscal 2019.
Why Did Aphria Stock Fall 7% on May 8?
On May 8, Aphria’s (NYSE:APHA) management announced that it agreed to repurchase its convertible senior notes from some holders outside of Canada.
Massachusetts Wants to Help Cannabis Businesses amid COVID-19
Massachusetts made medical cannabis essential amid the COVID-19 pandemic. However, recreational cannabis dispensaries had to shut down.
Will Hexo Rebound with Its Molson Coors CBD Deal?
Hexo (TSE:HEXO) has been struggling for a while now and things aren’t looking good. The stock has lost close to 70.2% year-to-date.
Marijuana Legalization in Mexico Isn’t Likely in 2020
Marijuana legalization in Mexico looks hazy this year. Mexico won’t see marijuana legalization before December 15—the end of the next legislative session.
Canopy Growth to Exit Africa, Close Another Canadian Facility
Canopy Growth announced another set of global operational changes to optimize its production, improve efficiency, and align its supply with the demand.
Why Analysts Had Mixed Reactions to Aphria’s Q3 Earnings
On April 14, Aphria (NYSE:APHA) reported its third-quarter earnings. For the quarter, the company reported revenues of 144.4 million Canadian dollars.
COVID-19 Ends Marijuana Legalization Campaign in Missouri
Marijuana legalization efforts started struggling in Missouri after the coronavirus pandemic hit. The campaign struggled to obtain the required signatures.
Wall Street Is Bearish after OrganiGram’s Q2 Results
OrganiGram’s second-quarter results didn’t meet the expectations. Many analysts downgraded the stock and cut the target price.
OrganiGram Posted Its Q2 Earnings, Stock Fell 12%
OrganiGram (NASDAQ:OGI) reported its results for the second quarter of fiscal 2020 on April 14 before the market opened. The results weren’t impressive.
Aphria Reported Impressive Q3 Results, Beat Expectations
On Tuesday, Aphria (NYSE:APHA) reported its third-quarter results. The company reported impressive third-quarter results and beat analysts’ expectations.
Cannabis Faces Barriers in Washington and Michigan
Washington has included cannabis on the list of essential items. However, the COVID-19 crisis has caused the state to make some strict changes.
OrganiGram: Analysts Aren’t Hopeful about Its Q2 Earnings
OrganiGram will report its results for the second quarter of fiscal 2020 on April 14 before the market opens. Analysts aren’t hopeful about the results.
Should Joe Biden Support Marijuana Legalization?
Marijuana is gaining a lot of attention amid the coronavirus pandemic. Many people think that Joe Biden should support marijuana legalization.
KushCo Posted Disappointing Q2 Results, Stock Rose 8%
KushCo’s second-quarter revenue was almost in line with analysts’ estimates. The company reported revenue of $30.14 million.
Will Aphria’s Q3 Earnings Lift the Cannabis Sector?
Analysts expect Aphria to report revenue of 130.6 million Canadian dollars in the third quarter—growth of 77.5% YoY and a sequential increase of 8.3%.
OrganiGram: Analysts Revise 2020 Estimates in April
Analysts have lowered the revenue estimates for OrganiGram for fiscal 2020. Analysts expect the revenue to be around 127 million Canadian dollars.
Will the Marijuana Industry Survive COVID-19?
Despite increased sales, the marijuana industry’s struggles haven’t ended. Temporarily closing stores and laying off employees will take a toll.
OrganiGram to Reduce Workforce by 45% Due to COVID-19
OrganiGram has joined the list of cannabis companies, like Canopy Growth and Aurora Cannabis, that will reduce their workforce.
Cronos Group: Analysts Revise Estimates in April
Cronos Group disappointed analysts and investors with its results for the fourth quarter of fiscal 2019. The company missed analysts’ revenue estimates.
Canopy Growth’s Vaporizer Device Gets Health Canada Approval
On April 3, Canopy Growth (NYSE:CGC)(TSE:WEED) announced that Health Canada issued a medical device license for Volcano Medic 2—its vaporizing device.
Comparing OrganiGram and Aphria’s Valuation Multiples
So far this year, OrganiGram Holdings (NASDAQ:OGI) and Aphria (NYSE:APHA) have lost 11.0% and 36.7% of their stock price.
Hexo Stock Tanks after Reporting Its Q2 Earnings
Today, Hexo (TSE:HEXO) reported its earnings results for the second quarter of fiscal 2020. The company reported revenues of 17.0 million Canadian dollars.
Analysts’ Recommendations after Charlotte’s Web’s Q4 Earnings
Charlotte’s Web Holdings reported its fourth-quarter earnings on March 24. For the quarter, the company missed analysts’ revenue and EBITDA estimates.
Analysts Cut Curaleaf’s Target Price after Its Q4 Earnings
Since Curaleaf reported its fourth-quarter earnings on March 24, Alliance Global Partners and Canaccord Genuity have lowered their target prices.
COVID-19 Pandemic Made Marijuana an Essential Item
Amid the coronavirus pandemic, marijuana has become an essential item in many US states. As a result, there was a surge in cannabis demand.
Wall Street Has a Bullish Outlook for Aphria in March
Aphria (NYSE:APHA) is one of the cannabis stocks that investors and analysts still like. They’re confident that the stock will outperform.
Charlotte’s Web Stock Rose after Its Q4 Earnings
Today, Charlotte’s Web Holdings (TSE:CWEB)(OTCMKTS:CWBHF) reported its fourth-quarter earnings. For the quarter, the company reported revenues of $22.8 million.
New York Senator Wants to Delay Marijuana Legalization
New York Senator Liz Krueger thinks that the state needs to deal with the coronavirus pandemic. The state doesn’t need to rush marijuana legalization.
Why Did Bank of America Upgrade Aphria and OrganiGram?
On March 19, Bank of America upgraded Aphria (NYSE:APHA) and OrganiGram Holdings (NASDAQ:OGI) due to the increased demand for cannabis.
Analysts Recommend a ‘Buy’ for Curaleaf before Its Q4 Earnings
As of Thursday, nine analysts covered Curaleaf. Among the analysts, eight recommend a “buy,” while one recommends a “hold.”
Tilray’s Q4 Earnings Force Analysts to Cut Its Target Price
Tilray (NASDAQ:TLRY) reported dismal results for the fourth quarter of fiscal 2019 on Tuesday. The losses widened in the fourth quarter.
What Do Analysts Recommend for Green Growth Brands?
After Green Growth Brands reported its earnings, Eight Capital downgraded the stock from “buy” to “sell.” Currently, three analysts follow the company.
OrganiGram: What Do Analysts Recommend Right Now?
As of February 28, OrganiGram Holdings (NASDAQ:OGI) was trading at 2.98 Canadian dollars—a fall of 6.6% since the beginning of this year.
What Can You Expect from IIPR’s Q4 Earnings?
IIPR will report its results for the fourth quarter of 2019 today after the market closes. Analysts expect the company to post revenue and EPS growth.
Minnesota’s Second Attempt at Marijuana Legalization
Marijuana is legal for medicinal purposes in Minnesota. Soon, lawmakers will present another bill for marijuana legalization in the state.
Singapore Government Asks Netflix to Block Marijuana Shows
Some countries still have very strict marijuana laws. Recently, Singapore’s government asked Netflix to block all marijuana shows and films in the country.
Pete Buttigieg’s Bold Stance on Marijuana Legalization
Pete Buttigieg took a bold stance to legalize marijuana. He said that he has a “Plan B” for marijuana legalization, which involves using Air Force One.
Bernie Sanders Vows to Legalize Marijuana in 50 States if Elected
Recently, at a rally, Bernie Sanders announced that he will legalize marijuana in all 50 states in the US if he wins the presidential election.
Congress Takes Steps in Favor of Cannabis Research
Congress held a hearing on January 15 to discuss the six cannabis-related reform proposals. Lawmakers discussed the problems that the US faces.
Cresco Labs Stock Rose after Securing $100 Million Loan
On Thursday, Cresco Labs announced that it signed an agreement for a senior secured term loan for an initial aggregate principal amount of $100 million.
Is There Hope for Aurora Cannabis in 2020?
Aurora Cannabis is one of the big names in the cannabis space. The company had a hard time in 2019 due to lower revenues and profitability.
Is Cresco Labs a Good Bet in January?
Analysts expect Cresco Labs to report revenues of $45.3 million in the fourth quarter to take the total revenue for 2019 to $131.9 million.